Please login to the form below

Not currently logged in
Email:
Password:

Skyrizi

This page shows the latest Skyrizi news and features for those working in and with pharma, biotech and healthcare.

Lilly reports positive data from its phase 3 ulcerative colitis trial

Lilly reports positive data from its phase 3 ulcerative colitis trial

For Crohn’s,   mirikizumab is in a close race with AbbVie’s IL-23 inhibitor Skyrizi (risankizumab), which recently met both primary endpoints of clinical remission and endoscopic response at week ... Skyrizi is also being evaluated in a phase 2/3

Latest news

More from news
Approximately 8 fully matching, plus 18 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...